GLP‑1 Weight‑Loss Drugs Spark Global Overhaul of Obesity Care
Prescriptions for GLP‑1 medicines such as Ozempic and Mounjaro have surged globally, creating supply shortages, spurring counterfeit markets, and forcing regulators from the U.S., Canada, Europe and India to tighten controls. The shift is redefining obesity as a chronic disease requiring medical oversight rather than a lifestyle choice.
Therapeutic Plasma Exchange Shows Temporary 2.5‑Year Biological Age Reduction, Study Finds
Researchers publishing in Aging Cell say a therapeutic plasma exchange protocol trimmed biological age by roughly 2.5 years in a small human trial, but the effect largely disappeared by the study’s end. The mixed results have ignited both excitement and...
Phase‑III Trial Shows Clascoterone 5% Boosts Hair Count 2.4‑Fold in Men with Androgenetic Alopecia
A Phase‑III study of clascoterone 5% topical solution demonstrated a 2.39‑fold increase in hair count after one year, positioning the acne drug as a promising therapy for androgenetic alopecia. The trial, involving 1,465 men, also confirmed a safety profile comparable...
Rubedo’s AI‑Designed Senolytic RLS‑1496 Begins First‑In‑Human Trials
Rubedo Life Sciences has started Phase 1 human trials of RLS‑1496, the first GPX4‑targeting senolytic drug designed by its ALEMBIC AI platform. The parallel trials in Europe and the United States aim to assess safety and dosing of a therapy that...
Microfluidic Lens Rivals Electronics for Glaucoma Monitoring
Can a microfluidic contact lens match electronic systems for glaucoma care while staying comfortable enough for daily wear? https://spectrum.ieee.org/smart-contact-lens-glaucoma-microfluidics?share_id=9388906
Carbios Posts €34.3 M FY25 Loss, Sets FY26 Plan to Scale Enzyme Recycling
Carbios announced a €34.3 million ($37 million) net loss for fiscal 2025, despite higher revenue, and laid out a FY26 strategy focused on scaling its enzyme‑based plastic‑recycling operations, securing financing for the Longlaville plant, and expanding a licensing model in Asia.
These Alzheimer’s Drugs Were Supposed to Revolutionize the Way We Fight the Disease. The Reality Is More Complicated.
A new Cochrane Library review casts doubt on the clinical value of Leqimbi and Kisunla, the two Alzheimer’s drugs hailed as breakthroughs in recent years. The analysis of multiple trials finds the medications produce little to no improvement in cognition,...
Lupin Receives Form 483 After USFDA Inspection of Somerset Unit
Lupin Ltd disclosed that the U.S. Food and Drug Administration issued a Form 483 after inspecting its Somerset, New Jersey manufacturing site from April 13‑17, 2026. The FDA cited three observations that may represent violations of the FD&C Act. Lupin said it will address...
5 Most Undervalued Biotech Stocks to Buy Right Now
ADMA Biologics (NASDAQ:ADMA) appears on a list of the five most undervalued biotech stocks, even as Cantor Fitzgerald downgraded the shares to neutral after a short‑seller report alleged channel‑stuffing and rising days‑sales‑outstanding. Cantor highlighted the lack of clear response from...
Protein Aggregates Damage Brain Vascular Barrier in Parkinson’s
Organ-on-a-chip technology demonstrates that Parkinson's-associated protein aggregates disrupt the brain's vascular barrier, leading to endothelial dysfunction and impaired blood flow. This insight highlights the vascular component of neurodegenerative disease. neuroscience
Brain-on-a-Chip Reveals How Parkinson's Proteins Weaken the Brain's Vascular Barrier
Researchers at Binghamton and Drexel used a microfluidic brain‑on‑a‑chip to study how Parkinson’s‑related alpha‑synuclein aggregates affect the blood‑brain barrier. The study showed that protein clumps cause endothelial dysfunction, barrier disruption, and vascular regression, leading to impaired blood flow. These findings...
Managing Infection Risks in BCMA Bispecific Antibody Therapy: Ajay K. Nooka, MD, MPH
The FDA granted full approval to teclistamab (Tecvayli), a BCMA bispecific antibody for relapsed/refractory multiple myeloma, despite grade 3‑4 infection rates of 50‑60 percent observed in early trials. Ajay K. Nooka, MD, MPH, explained that these infections occurred largely during the COVID‑19 pandemic...
GPT-Rosalind Lands: What OpenAI’s First Domain-Specific Life Sciences Model, the Codex Life Sciences Plugin & the Trusted Access Program Actually...
OpenAI unveiled GPT‑Rosalind on April 16, its first domain‑specific model built for life‑sciences tasks such as biochemistry, genomics, and protein engineering. Access is limited to a Trusted‑Access program that currently includes Amgen, Moderna, Thermo Fisher Scientific, the Allen Institute and...
Teva Recalls Over 300,000 Clonidine Transdermal Cartons After FDA Upgrades Recall Level
Teva Pharmaceuticals USA recalled more than 300,000 cartons of its Clonidine Transdermal System on March 19, after the FDA upgraded the recall classification because the product used an unapproved raw material. The move underscores heightened regulatory scrutiny of blood‑pressure therapies...
Pfizer Unveils Nanoparticle Platform to Target Tumors, Reduce Side Effects
Pfizer said today its Targeted Therapeutics Unit in Oncology R&D is advancing a nanotechnology platform that uses engineered nanoparticles to deliver drugs straight to cancer cells. The approach is designed to boost efficacy while cutting the collateral damage typical of...
FDA Approves TVTX, Philips Spectral CT, Rejects REPL; New Trials Unveiled
The U.S. Food and Drug Administration granted clearance to TVTX and Royal Philips' AI‑driven Spectral CT system, while rejecting the REPL gene‑therapy candidate. In the same week, several biotech firms disclosed fresh clinical‑trial launches and Carbios disclosed a deeper fiscal‑2025...
Lilly CEO Sees Weight-Loss Drugs Reaching About Half of Potential Users at Peak
Eli Lilly CEO David Ricks told investors that GLP‑1 weight‑loss drugs will likely reach only about half of the 500 million people worldwide who could benefit, due to institutional and cost barriers. He noted that today roughly one in ten eligible patients...
Retatrutide - Possibly Better than Semaglutide B/C Lower Nausea/Side Effect Profile, but Higher Heart Rate
Retatrutide, a triple‑agonist peptide, is generating buzz for delivering dramatic weight loss at doses of 8‑12 mg, rivaling semaglutide while causing fewer nausea complaints. Early users note that appetite suppression diminishes after several weeks, yet the drug continues to support weight‑maintenance...
Pfizer Vaccine Safe, Effective in Juvenile Inflammatory Disease
A multi‑center trial published this week confirms that Pfizer's mRNA COVID‑19 vaccine is both safe and effective for children suffering from juvenile inflammatory diseases such as juvenile idiopathic arthritis and inflammatory bowel disease. The study tracked 312 participants aged 5‑17,...
Hazel Szeto, SS-31 Peptide, the World's First FDA-Approved Mitochondria-Targeted Drug (Longevity Summit, 2025)
SS‑31 (elamipretide), the first FDA‑approved mitochondria‑targeted drug, is being promoted on TikTok as a vision enhancer, despite its approval only for a rare mitochondrial disease. Clinical data for age‑related macular degeneration (AMD) show the drug failed to meet endpoints, with...
Peptides: Unregulated, Risky, and Growing in Popularity
"What's your star sign?" "I'm a Taurus." "Cool, and what's your peptide stack?" Special Lifers episode on Peptides Part 1 with Sunita Mohanty Spotify: https://t.co/nRCBnLOjqm Apple: https://t.co/iibWpZHNZ7 Youtube: https://t.co/ijtPosgt4t Timestamps: (00:00) Intro (00:04) Peptides everywhere (00:42) Meet Sunita and Ultralight (01:08) Regulatory whiplash explained (01:58) Stacks and the gray area (03:34) Black market...
R&D Hype Unchecked: No Accountability for Drug Promises
Nice article by @TClozel in @FastCompany. Link in comments. The funny thing is that every company he mentioned and many others promised many years ago and still promise cheaper, faster, higher PoS drugs and many of them do not...
Trump Expected to Loosen Restrictions on Psychedelic Drugs
President Trump is set to sign an executive order that will loosen federal restrictions on psychedelic drugs such as LSD, ecstasy and psilocybin. The order earmarks $50 million for state‑level ibogaine research, with Texas slated to receive the first grant. It...
Imeglimin. A New and Novel Drug Thats Better than Metformin
Imeglimin, a mitochondrial‑targeted antidiabetic agent, is emerging as a novel alternative to metformin. Pre‑clinical studies show it restores mitochondrial function in skeletal muscle and pancreatic β‑cells, enhancing insulin secretion and reducing oxidative stress. Phase‑3 trials report HbA1c reductions of 0.6‑0.9%...
How Nanomedicine Gets Inside Your Cells and Treats You From the Inside Out
Nanomedicine is moving from concept to clinic as researchers use lipid‑nanoparticle carriers to deliver synthetic mRNA and siRNA directly into patient cells. The approach lets liver cells produce missing proteins such as factor VIII for hemophilia A, while silencing harmful proteins like...
Genetic IL6R Blockade Shows No Impact on Disease or Longevity
Genetic interleukin-6 receptor blockade, chronic disease risk, and longevity: results from the women’s health initiative "Genetic IL6R blockade was not associated with incident chronic-disease risk, including invasive cancer and longevity, in a large, ethnically diverse cohort of postmenopausal women. No significant...
Trump Administration to Review Ibogaine for PTSD, Opens Federal Research Path
President Trump is set to sign an executive order this week that will direct federal agencies to study ibogaine, a psychedelic currently classified as a Schedule I drug, for its potential to treat PTSD and traumatic brain injury. The move does...
UCSF Pushes Forward Treg Cell Therapy to Prevent Type 1 Diabetes
UCSF scientists are advancing a regulatory T‑cell (Treg) therapy aimed at preventing type 1 diabetes, leveraging the center’s legacy of biomarker discovery and the 2022 FDA‑approved drug Teplizumab. The approach could reduce reliance on lifelong insulin and immunosuppressive drugs, a key...
UCB to Acquire Neurona Therapeutics for Up to $1.15 Billion, Boosting Epilepsy Portfolio
Belgian biopharma UCB announced a deal to buy U.S.‑based Neurona Therapeutics for up to $1.15 billion, with $650 million paid upfront and up to $500 million in milestones. The acquisition strengthens UCB’s epilepsy franchise and is expected to lift adjusted EBITDA into the...
Endobronchial Valves Offer New Hope for Severe COPD Patients
Pulmonx's Zephyr endobronchial valves, approved by the FDA in 2018, are giving severe COPD patients a minimally invasive way to regain lung function. More than 40,000 people worldwide have received the treatment, and a New Jersey patient recently reported walking...
Storm Therapeutics Secures $56 Million Series C to Push METTL3 Cancer Drug Into Phase 2
Storm Therapeutics announced a $56 million Series C financing led by Pfizer Ventures, M Ventures and other pharma‑backed investors. The cash will fund a Phase 2 monotherapy study of STC‑15, a first‑in‑class METTL3 inhibitor, in hard‑to‑treat sarcomas. The round signals growing confidence in epitranscriptomic...
Design‑First Protein Engineering Delivers Round‑One Success
Protein engineering has a dirty secret: most of the work is in the lab, not the algorithm. You design, you test, most variants fail, you iterate for months. Scala Biodesign's bet is that the design layer can do most of that...
NovaSeq 6000 Two‑color Chemistry Creates T>G Artifact
NovaSeq 6000's two-color chemistry introduces a recurrent T>G substitution artifact that doesn't show up on HiSeq X10's four-color chemistry. Germline and high-VAF somatic calls are fine. Low-VAF mosaicism calls are not. https://t.co/9PknN8Vyrb
OpenAI Launches GPT‑Rosalind, a Life‑sciences LLM for Drug Discovery
OpenAI unveiled GPT‑Rosalind, a domain‑specific large language model built for life‑science research, and made it available as a research preview in ChatGPT, Codex and its API. The company said the model will help biotech and pharmaceutical teams accelerate early‑stage discovery,...
Never Confuse DNA Plus/Minus Strands Again
1/17 Confused by plus/minus strands, coding/template, or forward/reverse in DNA data? You're not alone. Here's how to never mix them up 🧵 https://t.co/4kVXfhJssL
Implantable Islet Cells May Eliminate Insulin Injections
Implantable islet cells could control diabetes without insulin injections by Anne Trafton @MIT Learn more: https://t.co/aPCxukXMW1 #MedTech #HealthTech #Tech #TechForGood https://t.co/IwjlYaJitu
GLP-1 Receptor Agonists and Risk of Suicide or Suicide Attempts – A Nationwide Cohort and Self-Controlled Case Series Study
A nationwide Danish registry study examined whether glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs) increase suicide or suicide attempts compared with active comparators—SGLT‑2 and DPP‑4 inhibitors. Across two new‑user cohorts totaling over 200,000 GLP‑1 RA initiators, adjusted hazard ratios showed no elevated risk...
China Favors Grassroots, Market-Driven Trials; US Stays Centralized
Interesting look at how China may have a more grassroots and market-oriented approach to early, experimental trials vs. the American, centralized politburo approach:
Fish‑skin Graft with Silicone Accelerates Wound Healing
Kerecis Shield: Fish-Skin Graft with Silicone Layer for Faster Wound Healing by @IntEngineering #MedTech #HealthTech #TechForGood #Tech https://t.co/k1FaNFInaH
Major UKHSA Study Finds Maternal RSV Vaccination Reduces Infant Hospitalization Risk by More Than 80%
Researchers from the UK Health Security Agency presented the largest real‑world evaluation of maternal RSV immunisation, showing that infants whose mothers received the bivalent Prefusion F vaccine at least two weeks before delivery experienced an 81.3% drop in RSV‑related hospitalisations. The...
Partnering with Epigen
Dr. @M_S_Ringel is a knowledge fountain. COO of @lifebiosciences & a world's expert in epigenetic rejuvenation. Formerly Senior Partner @BCG for 20 years, it's a thrill to be working with him on the trials
Blood‑based ECM Protein Clock Predicts Biological Age and Disease
An Extracellular Matrix Aging Clock Based on Circulating Matrisome Proteins Predicts Biological Aging and Disease https://t.co/3VOwhGCz5S
Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal...
Agenus presented Phase II data showing that a combination of botensilimab, balstilimab and the allo‑iNKT cell therapy agenT‑797 achieved a 77% disease‑control rate in PD‑1‑refractory gastroesophageal adenocarcinoma. Patients who received an induction cycle of agenT‑797 before the full regimen experienced median...
Pregnancy Vaccine Reduces Baby Hospital Admissions for RSV by 80%
The UK Health Security Agency reports that a maternal RSV vaccine administered from 28 weeks gestation reduces newborn hospital admissions for respiratory syncytial virus by more than 80%. The vaccine offers up to 85% protection when given at least four...
A Robust RP-HPLC Method for Simultaneous Estimation of Paracetamol and Nefopam in Human Plasma: Design of Experiments Approach
A rapid RP‑HPLC method using a Quality by Design framework was validated for simultaneous quantification of paracetamol and nefopam in human plasma. The C18 column with an acetonitrile/0.1 % orthophosphoric acid mobile phase achieved retention times of 6.22 min for paracetamol and...
Viral Immunity and Behavior Sustain Low Mpox Rates
A new Nature Communications study reveals that Los Angeles’ persistent, low‑level mpox incidence is driven by repeated viral introductions and a return to pre‑outbreak sexual behavior patterns. Genomic sequencing traced multiple independent importations rather than a single endemic chain, while mathematical...
AI Pharma Success Measured by Speed, Cost, Not Approvals
Very often I am being asked when will the first drugs designed using AI receive regulatory approval. The answer is very simple - there are several drugs that were already approved. For example, the first antibody to receive regulatory approval...
New PARP Inhibitor Resistance Mechanisms Found in Ovarian Cancer
A recent British Journal of Cancer study uncovers drug‑specific resistance mechanisms to PARP inhibitors in ovarian cancer, highlighting alterations in PARP trapping, replication‑fork protection, and chromatin‑remodeling. The research shows that resistance is not limited to homologous recombination restoration but involves...
Mammary Organoid Depot Enables Post-Surgery Chemo, Regeneration
Researchers have created a mammary organoid‑based depot that delivers a pH‑responsive doxorubicin prodrug directly to the surgical site while simultaneously regenerating breast tissue. The engineered organoids mimic lactation, loading drug‑laden lipid droplets into milk‑fat globules that are secreted locally, achieving...
Sex Differences Crucial for Glucagon Obesity Drug Efficacy
Male and female bodies respond differently to glucagon-based obesity drugs, and FGF21 plays an important role—especially in females. This means future treatments need to account for sex differences to be effective and safe. https://t.co/Z9gllk02Dj